Analyst Ratings for Esperion Therapeutics (ESPR)
ESPR Rating Summary
ESPR Price Target Summary
- Highest: $2.90 (BofA Securities)
- Lowest: $2.00 (Northland)
- Average: $2.45
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$2.45 (+25.6%)
* Over Last 12-Mos
Rating Score: 4.7 / 10
Percentile Rank: 48%
Avg. $ Target:
$2.45 (+25.6%)
* Over Last 12-Mos
Rating Score: 4.7 / 10
Percentile Rank: 48%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/3/2024 | BofA Securities » Updated 2/28/2024 |
Jason Zemanski | Downgrade | Neutral (Buy) |
2.90 (2.80) |
2.92 (1.95) |
-33.22% | Details |
| 11/20/2023 | JPMorgan | Jessica Fye | New Coverage | Neutral (N/A) |
N/A (N/A) |
1.11 (1.95) |
75.68% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
